Narcolepsy with cataplexy, which is a hypersomnia characterized by excessive daytime sleepiness and cataplexy, is a multifactorial disease caused by both genetic and environmental factors. Several genetic factors including HLA-DQB1*06:02 have been identified; however, the disease etiology is still unclear. Epigenetic modifications, such as DNA methylation, have been suggested to play an important role in the pathogenesis of complex diseases. Here, we examined DNA methylation profiles of blood samples from narcolepsy and healthy control individuals and performed an epigenome-wide association study (EWAS) to investigate methylation loci associated with narcolepsy. Moreover, data from the EWAS and a previously performed narcolepsy genome-wide association study were integrated to search for methylation loci with causal links to the disease. We found that (1) genes annotated to the top-ranked differentially methylated positions (DMPs) in narcolepsy were associated with pathways of hormone secretion and monocarboxylic acid metabolism. (2) Top-ranked narcolepsyassociated DMPs were significantly more abundant in non-CpG island regions and more than 95 per cent of such sites were hypomethylated in narcolepsy patients. (3) The integrative analysis identified the CCR3 region where both a single methylation site and multiple single-nucleotide polymorphisms were found to be associated with the disease as a candidate region responsible for narcolepsy. The findings of this study suggest the importance of future replication studies, using methylation technologies with wider genome coverage and/or larger number of samples, to confirm and expand on these results.
Introduction
Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness, cataplexy (sudden loss of muscle tone in response to strong emotion), and pathological manifestations such as hypnagogic hallucinations (dream-like experiences occurring at sleep onset) and sleep paralysis (inability to move at wake and REM sleep transitions). The peak age of onset is around 15 years and is similar for both sexes [1] . The prevalence of narcolepsy is estimated to be 0.16%-0.18% in Japan, in contrast to only 0.02%-0.06% in the United States and Europe [2] . Family and twin studies have indicated that narcolepsy is a multifactorial disease, triggered by both genetic and environmental factors [2] with the relative risk for first-degree family relatives being 10-to 40-fold higher than in the general population [2] , and the concordance rate between monozygotic twins being approximately 20%-30% [3] . Narcolepsy is likely to be caused by the loss of hypocretin-(orexin-) producing cells in the lateral hypothalamus; however, a detailed etiology and the mechanism by which loss of orexinproducing cells occurs still remain to be elucidated.
To date, a certain number of genetic studies have been performed, identifying several genetic factors associated with narcolepsy. The most firmly established is a strong association of the human leukocyte antigen (HLA) class II region, specifically the HLA-DQB1*06:02 allele [4, 5] . Almost all patients with narcolepsy, across all ethnic groups, carry HLA-DQB1*06:02, whereas around 10 per cent of the general Japanese population carry this allele, suggesting that HLA-DQB1*06:02 alone cannot explain the entire genetic component of the disease [5] . Previous studies, investigating other HLA alleles linked to this disease, reported an association of HLA-DPB1 after adjustment for the effects of HLA-DR and HLA-DQ [6, 7] . In addition, recent genome-wide association studies (GWASs) have identified several new narcolepsy-associated genes including CPT1B/CHKB [8] , TCRA [9] [10] [11] , P2RY11 [11, 12] , TNFSF4 [10] , CTSH [10] , TCRB [11] , ZNF365 [11] , CCR1/CCR3 [13] , and the IL10RB-IFNAR1 [11] locus. However, the contribution of singlenucleotide polymorphisms (SNPs) in these gene regions to narcolepsy was assessed as relatively small [14] , suggesting that other unidentified genetic factors are associated with the disease.
In addition to genetic factors, environmental factors, such as exposure to the H1N1 ASO3-adjuvanted pandemic vaccine (Pandemrix) or Streptococcus pyogenes infections, are predicted to play a certain role in the pathophysiology of narcolepsy [15, 16] . Epigenetics is one of the most rapidly developing fields in biology and generally refers to potentially heritable and functionally relevant modifications of gene expression and chromatin structure, without any change in the primary DNA sequence [17] . Epigenetic modifications functionally interact with a complex combination of environmental factors, genetic variations, and cellular phenotypes [18] and may thus contribute to the etiology of complex diseases [17] .
DNA methylation, one of the major forms of epigenetic modification, is the most widely studied in human disease [17] . Recently developed array-based technologies enable us to mark patterns of disease-related methylation in a genome-wide manner [17] . However, to the best of our knowledge, there is no study which has examined DNA methylation profiles in typical narcolepsy with cataplexy patients using this technology.
In this study, we thus performed an epigenome-wide association study (EWAS) of DNA methylation for narcolepsy to identify loci in which methylation levels are associated with the disease.
Subsequently, since it is impossible to know whether levels of methylation have a causal effect on a disease from EWAS data alone, we used an integrative approach to combine our EWAS results from those of a GWAS that we previously performed [13] , to identify sites of differential methylation that might be under the control of genomic variants associated with narcolepsy. Our results provide the first evidence to date that DNA methylation may play a causative role in the pathogenesis of narcolepsy.
Methods

Participants
DNA samples of patients with narcolepsy (N = 26) and healthy individuals (N = 20) were collected from unrelated individuals living in mainland Japan. Narcolepsy with cataplexy was diagnosed according to the International Classification of Sleep Disorders 2nd edition [19] : (1) patients who had excessive daytime sleepiness and clear-cut cataplexy; (2) HLA-DQB1*06:02 positive; and (3) not diagnosed as having another sleep disorder, or other neurodevelopmental or major psychiatric disorders. Healthy control participants were interviewed by psychiatrists to exclude those with a history of a sleep disorder or a major psychiatric illness. The demographic characteristics of analyzed samples are provided in Supplementary Table 1 . We also utilized GWAS data from 371 Japanese patients with narcolepsy, and 1476 Japanese healthy controls, from a previous study [13] . There was no significant demographic difference between these participants for the GWAS and those for the EWAS.
Written informed consent was obtained from all participants and ethical approvals were obtained from the research ethics committees of all relevant institutions.
DNA methylation analysis
DNA methylation profiles across the genome were examined with a DNA methylation array (Infinium HumanMethylation27 BeadChip, Illumina, Inc., San Diego, CA). Genomic DNA samples (Case, N = 26; Control, N = 20) were extracted from peripheral blood. DNA samples were first treated with sodium bisulfite to convert unmethylated cytosine residues to uracil and then isothermally amplified in a whole-genome amplification step. Subsequently, amplified and fragmented DNA was hybridized to locus-specific 50mer probes with two bead types, one corresponding to methylated cytosine (C) and the other corresponding to unmethylated cytosine (T). Finally, allele-specific extension using the hybridized DNA as a template was performed, which determined the methylation level at each locus for each sample. The methylation arrays were imaged with a high-precision scanner (iScan system, Illumina, Inc.) and signal intensities corresponding to methylated or unmethylated signals were extracted by GenomeStudio Software (Illumina, Inc.). A β value was calculated as the ratio of signal from a probe at a methylated site to the total signal intensity and ranged from 0 (unmethylated) to 1 (completely methylated). Additionally, an M value, which is the logit transformation of β, was used for association analyses, since the M value has been reported to be statistically more valid than the β value for the differential analysis of methylation levels [20] .
Data filtering and normalization
The β value of each probe returned by Illumina's GenomeStudio Software has a detection p value, which represents how well the measured intensity of a target site can be distinguished from background noise. A lower detection p value means that the assay performance for a target site is high. We first treated β values with a detection p value ≥ 0.01 as missing values and calculated call rates for each probe. Probes that met the following conditions were included in the subsequent EWAS analysis: (1) those with a call rate >95 per cent, (2) those on an autosomal chromosome, (3) those not including a SNP having a minor allele frequency (MAF) ≥ 0.05, and (4) those not reported as cross-reactive [21] , i.e. having the possibility to cohybridize to alternate sequences that are highly homologous (less than four base mismatches among 50mer probe sequences) to the target sequences (Supplementary Figure 1) . After filtering, data were normalized in the following steps: firstly, color channel bias correction and quantile normalization (correction for the distributions of the pooled probes) were performed using the Lumi software [22] , and secondly, batch effects were corrected with using the ComBat software [23] .
Normalized β values were converted to M values via logit transformation for regression analysis.
Prediction of DNA methylation ages as part of a data quality check DNA methylation age (DNAm age), which is defined as age predicted from DNA methylation profiles, was estimated for each sample, using the methylation array data and a reported algorithm [24] . The correlation between estimated DNAm ages and chronological ages was then examined in both case and control groups, to evaluate the reliability of the assay.
Prediction of the proportions of leukocyte subtypes
As our DNA samples were extracted from whole blood, an estimation of the proportions of leukocyte cell types was conducted following a published algorithm [25] . Proportions of natural killer (NK) cells, B cells, CD4 + T cells, CD8 + T cells, monocytes, and granulocytes were estimated and used to adjust for the effect of leukocyte cell type differences in regression analysis.
Epigenome-wide association analysis
Differentially methylated positions (DMPs) between case and control participants were investigated by linear regression analysis with adjustments for the effects of age, sex, body mass index (BMI), smoking status, and the predicted proportions of leukocyte subsets. M values were used in the regression analysis. In order to rank DMPs for biological importance, we employed a combinedrank scheme [26] . Rankings based on p values and those based on β value differences between case and control participants [Δβ; (adjusted case β value) − (adjusted control β value)] were thus combined to prioritize DMPs for their importance not only in terms of statistical significance, but also effect size.
Pathway analysis
Pathway analysis was carried out to map the genes annotated to the 100 top-ranked DMPs to biological pathways, using the MetaCore software (version 6.24 build 67895, Thomson Reuters, New York, NY). The top-ranked genes were examined for any statistical enrichment of biological process or molecular function gene sets from the GO database (http://geneontology.org/) [27] . Gene sets with more than 700 registered genes were filtered out from the results because such gene sets have a tendency to represent broader categories with ambiguous biological meanings [28] . Gene sets less than five top-ranked genes were also filtered out because such gene sets might be considered less valid as "gene sets." Additionally, we performed another GO-based pathway analysis using the goseq software [29] . The goseq pathway analysis enables us to correct for gene length bias and the effect of a background gene set analyzed by the Illumina's array [30] . Pathways identified in both MetaCore and goseq analyses were regarded as true significantly associated pathways. Significant gene sets were clustered using a multidimensional scaling, and their biological functions were determined. Cytoscape (http://www.cytoscape.org/) was used to illustrate such gene-set clusters schematically.
Construction of a methylation QTL reference
For an integrative analysis of the GWAS and EWAS data, we took advantage of methylation quantitative-trait loci (meQTL) signatures. To date, several studies have reported cis-and transmeQTLs; however, there is no comprehensive meQTL reference that includes all reliable meQTLs reported across multiple studies. In this study, we investigated studies which examined meQTLs with a sample size larger than 500 and which disclosed full lists of the detected meQTLs. The five studies shown in Supplementary Table 2 were finally included in the meQTL reference that we constructed [31] [32] [33] [34] [35] . MeQTLs reported in at least two studies were selected as reliable meQTLs. Among the five studies, only the study performed by McClay et al. [32] employed a sequence-based methylation measurement method. Since four of the five studies employed Illumina's 450K BeadChip array, we first extracted meQTLs based on the probes of this array. As for the sequence-based study, we converted the meQTLs of the extracted methylation regions to those of the corresponding probes, for comparison to the studies based on Illumina's 450K BeadChip array. If a methylation region included more than two array probes, the meQTL was divided into multiple meQTLs. Furthermore, as the five studies used different SNP typing platforms, we needed to modify the meQTL lists from each of the five studies to compare the meQTLs. To do this, we first constructed a list of SNPs in high linkage disequilibrium (LD) using genotype data from the 1000 Genomes Project (Supplementary Figure 2) [36, 37] . As all five meQTL studies were performed mainly in Caucasian populations, we included in the analysis only the genotype data for European participants denoted by the "Super Population Code" EUR (European), on the 1000 Genomes Project website (http://www.internationalgenome.org/category/population/). SNP pairs with relatively high LD (r 2 ≥ 0.5)
were extracted and filtered for a call rate > 90 per cent, HardyWeinberg Equilibrium (HWE) p value > 0.01, and MAF > 0.5 per cent (Supplementary Figure 2) . Next, meQTL SNPs were examined using the SNP LD list, and if a high LD to another SNP was found, the association of the high LD SNP with the methylation site was added to the initial meQTL list. MeQTLs included in at least two out of the five studies were then extracted using the modified meQTL lists (Supplementary Figure 2) . In the last step, SNPs which were in high LD (r 2 ≥ 0.5) with meQTL SNPs were considered again, and a final meQTL list was constructed.
Integrative analysis of the GWAS and the EWAS
For integrative analysis, the genotype data of our previous GWAS [13] were reanalyzed, excluding samples used in the current EWAS. The details of the initial GWAS, which included a total of 371 cases and 1476 controls, are described elsewhere [13] . An imputation analysis using the GWAS genotype data was performed utilizing the IMPUTE2 software [38] , with the reference dataset from 1000 Genomes Phase 3 haplotypes [38] . For the association analysis, SNPs which met the following conditions were included; (1) call rate > 95 per cent, (2) HWE p value > 0.001 and (3) MAF > 5 per cent. Since a strong association between narcolepsy and HLA-DQB1*06:02 has previously been demonstrated, SNPs in the HLA gene regions (chr6:28,000,000-34,000,000, hg19) were excluded and a total of 4,078,447 SNPs were used for the integrative analysis. The association analysis was conducted by comparing SNP allele frequencies in case and control groups using PLINK v.1.9 [39] . An outline of our integrative approach for GWAS and EWAS data is described in Figure 1 . SNPs with a p value of <0.01 from the GWAS and methylation sites that were ranked in the top 5 per cent in the EWAS were regarded as candidate SNPs and methylation sites, respectively ( Figure 1A) . Finally, we used our meQTL reference set to identify meQTLs at which SNP and methylation sites were detected as candidates in this integrated analysis ( Figure 1B ).
Statistical analysis
In the EWAS analysis, DMPs were evaluated using the following two criteria: a false-discovery rate (FDR) and the combined rank. In the MetaCore-based pathway analysis, pathways were assessed using an FDR threshold of 5 per cent. If a pathway identified by Metacore analysis also showed nominal significance (p value < 0.05) in the subsequent goseq-based pathway analysis, the pathway was considered as a candidate for being associated with narcolepsy. To interpret the relationship between candidate pathways, multidimensional scaling based on Jaccard distance was performed to cluster pathways. Jaccard distance was calculated based on the genes annotated to each candidate pathway. All analyses other than MetaCore-based pathway analysis were performed using the R software.
Results
Data quality check
DNA methylation profiles of narcolepsy and healthy individuals were examined using the array-based technology. The overall assay performance was assessed, first examining the detection p values of all probes for each sample. We confirmed that >99.7 per cent of probes had a detection p value of <0.01 across all samples. The density plots of β values before and after quantile normalization were assessed visually, with all normalized plots showing the standard bimodal distribution of properly normalized data (Supplementary Figure 3) . Furthermore, DNAm age (estimated using the methylation array data) and chronological age showed a strong correlation (Pearson's correlation coefficient up to 0.934), supporting the quality of the data (Supplementary Figure 4) .
Epigenome-wide DNA methylation analysis
After the DNA methylation status of each sample was obtained, a stringent EWAS data filtering and normalization procedure were performed, with a total of 22 975 probes examined (Supplementary Figure 1) . In order to account for a potential effect of leukocyte composition bias, we next predicted the proportions of leukocyte subtypes for all participants. When we compared the distributions of leukocyte subtypes between the case and control groups, a slight difference was observed, especially in the B cell comparison (p = 0.023; Supplementary Figure 5) .
In order to investigate DMPs associated with narcolepsy, regression analyses adjusting for the effects of age, sex, BMI, smoking status, and leukocyte subtype were consequently performed. Fourteen probes showed significance at an FDR of 5 per cent (Figure 2A, Supplementary Table 3 ) and top-ranked probe was cg09855435, which was located in IL22RA2 (interleukin 22 receptor subunit α 2). However, these significant DMPs had small Δβ values between case and control participants, suggesting that they might not necessarily reflect biological significance [40] . Therefore, to rank DMPs, in regard to both statistical significance and effect size (Δβ), we used a combined-rank scheme [26] . The results from the 100 top-ranked probes are shown in Figure 2B , Table 1, and Supplementary Table 4 . The top-ranked DMP, cg11719784, was located upstream of ADORA1 (adenosine A1 receptor) and hypomethylated in the case participants (Δβ = 6.0 per cent, p = 1.7 × 10 −4 ; Table1, Supplementary Table 4) . The probe cg09855435 in the IL22RA2 region also featured in this list (Δβ = 3.9 per cent, p = 1.80 × 10 −6 ). Among the 100 top-ranked DMPs, 66 sites were located outside of CpG island regions. The majority of the 27K array probes were designed to CpG island regions, and thus, the proportion of top-ranked probes outside of these regions (66/100 probes) was significantly higher than for all probes on the array (6118/22 975 probes; p = 7.32 × 10 Table 6 ). In contrast, among the 34 top-ranked probes targeted to CpG island, 19 were found to be hypermethylated in case participants (p = 4.34 × 10 −9 , Supplementary Table 6 ).
Pathway analysis
To investigate the biological pathways associated with genes annotated to the 100 top-ranked DMPs, two analyses were performed. The MetaCore software is based upon expert-curation of pathways, whereas the goseq software implements adjustment for background signals and gene length. From both analyses, we detected eight pathways associated with narcolepsy (Table 2, Figure 3 ). Several pathways related to secretion, especially hormone secretion, were identified (Table 2, Figure 3) . Furthermore, monocarboxylic acid metabolism was also found to be significantly associated with narcolepsy (Table 2, Figure 3 ).
Integrative analysis of the GWAS and the EWAS
Next, we performed an integrative analysis to identify DMPs for which methylation status was affected by SNP genotype. Firstly, we constructed a meQTL reference, searching meQTLs detected in at least two out of the five published studies that we identified as being appropriate for this purpose (see Methods). A total of 515,215 SNP-methylation pairs were selected as reference meQTLs (Supplementary Figure 2) . Next, we identified meQTLs for which both SNP genotype (from GWAS) and methylation status (from EWAS) showed association with narcolepsy. As a result, 19 meQTLs were detected, all of which were cis-meQTLs located in the CCR3 (chemokine receptor 3) region (Supplementary Table 7 ). One meQTL, rs60939770 and cg04111761, was reported as a meQTL in both the studies of Bonder et al. [35] and Gaunt et al. [33] , and the other 18 meQTLs were derived from this meQTL. The level of methylation of cg04111761 has been reported to be significantly higher for the minor allele (G) of SNP rs60939770 (p = 1. 34 × 10 −190 ) [35] . In the narcolepsy GWAS, the G allele frequency of SNP rs60939770 was found to be lower in patients with narcolepsy (p = 8.9 × 10 −5
, OR = 0.59), from which we would expect that the methylation of cg04111761 would also be less in patients with narcolepsy. Indeed, the cg04111761 methylation level was found to be lower in case participants in the EWAS (Supplementary Table 7) , and the DMP was among the top 5 per cent of ranked DMPs.
Discussion
In this study, we investigated methylation profiles associated with narcolepsy in a genome-wide manner for the first time, to the best of our knowledge. Fourteen methylation sites were identified as DMPs associated with the disease at an FDR of <5 per cent and the top-ranked CpG site located in the first intron of IL22RA2 was found to be significantly hypomethylated in patients with narcolepsy after adjusting the effects of covariates, including age, sex, BMI, smoking status, and proportions of leukocyte cell types. However, since some of these had small Δβ values, they may not have had biological significance. Therefore, we employed a combined-rank approach to find biologically important DMPs. The top-ranked DMP was located upstream of the ADORA1 gene and was found to be approximately 6 per cent hypomethylated in patients with narcolepsy. Although complex interactions between methylation patterns and gene expression have been revealed by recent studies [41] , DNA hypomethylation in upstream gene regions is widely recognized as being associated with higher levels of gene expression [42] . Therefore, it is possible that ADORA1 is expressed at higher levels in patients with narcolepsy than in control participants. Adenosine is one of the important neurotransmitters regulating sleep [43] , having been reported to promote sleep and increase EEG slow wave activity [44] . There are four adenosine receptors, A 1 A 2A , A 2B , and A 3 , with the A 1 receptor known to play a role in the context of sleep [44] . This receptor is highly expressed throughout the brain [45] and is reported to be involved in modulating sleep homeostasis through several mechanisms, including inhibition of hypocretin/orexin neurons in the lateral hypothalamus [46] and cholinergic neurons in the mesopontine tegmentum [47] . It is unclear whether the observed hypomethylation of the CpG site upstream of ADORA1 might be the cause or effect of narcolepsy, but regardless, the change in methylation may contribute to the pathophysiology of the disease. Future studies, especially those using brain samples, will be needed to confirm this ADORA1 association.
When we focused on the 100 top-ranked DMPs, those located outside of CpG islands were found to be significantly over-represented in comparison to the regions represented on the array. Moreover, more than 95 per cent of DMPs located outside of CpG islands were hypomethylated in patients with narcolepsy. Interestingly, exome sequencing in families with autosomal dominant cerebellar ataxia, deafness, and narcolepsy (ADCA-DN) demonstrated that mutations in the RFTS (replication foci targeting sequence) domain of DNMT1 (DNA methyltransferase 1) caused the disease [48] and genome-wide methylation analysis revealed the presence of hypomethylation in CpGs with 0%-10% and 80%-95% methylation in patients with ADCA-DN [49] . One study has reported the DNA methylation patterns of non-CpG island promoters to be almost identical to those of CpG islands [50] , and in this context, therefore, the hypomethylation of non-CpG island DMPs might be expected to affect gene expression. Several other studies have reported that different biological mechanisms operate in CpG and non-CpG islands [51] . In general, DNA methylation is known to decrease with age, but sites at CpG islands and shores are reported to be exceptions to this rule, with methylation in these locations potentially increasing during life [51] . Such results therefore suggest that CpG islands and non-CpG islands do indeed have distinct mechanisms governing DNA methylation by the actions of DNA methyltransferases, which may cause the decreased methylation of non-CpG island regions in participants with narcolepsy, although the precise mechanism remains unclear.
In this study, we performed pathway analyses to examine whether genes annotated to top-ranked methylation sites had relevance for specific biological processes. Eight pathways were detected, which could be divided into two broad categories; one category represented pathways associated with the secretion or release of hormone and the other consisted of metabolic pathways. It is perhaps not surprising that pathways associated with hormone secretion or release were found, since hypocretin is known to interact with various neuropeptides and hormones [52] . Loss of hypocretin neurons, which occurs in most patients with narcolepsy with cataplexy, might thus be expected to affect such neuropeptides and/or hormones. Of note, we found that GALR1 (galanin receptor 1) was a member of these hormone-related pathways. One probe, cg15343119, that was located in CpG island upstream of GALR1 was hypermethyalted in patients with narcolepsy. We know that both hypocretin and galanin are orexigenic factors and reciprocal effects for hypocretin and galanin have been reported in the control of energy balance [53] . Moreover, the adenosine receptor gene was also found to be a member of the hormone secretion-or release-related pathways. Previous work has shown that adenosine levels in hypocretin neuron-lesioned rats do not change following sleep deprivation, whereas in rats without these lesions, adenosine levels increase [54] .
Pathway analysis also revealed that monocarboxylic acid metabolism is associated with narcolepsy. This is intriguing because fatty acids are a type of monocarboxylic acid, and we previously reported an association between dysfunctional fatty acid beta-oxidation and narcolepsy [55] . A SNP located upstream of CPT1B (carnitine palmitoyl-transferase 1B) was first identified as a novel narcolepsy-associated SNP by GWAS [8] . Later studies found that CPT1B expression levels were significantly higher in patients with narcolepsy and that lower acylcarnitine levels were observed in a percentage of patients [55] . Moreover, oral L-carnitine administration has been shown to be effective for improving excessive daytime sleepiness in narcolepsy [56] . In the current study, nine of the genes annotated to top-ranked DMPs were associated with a role in monocarboxylic acid metabolism. Among these genes, ACADL (acyl-CoA dehydrogenase, long chain), which encodes human long-chain acyl-CoA dehydrogenase, plays a particularly important role in mitochondrial β-oxidation of straight-chain fatty acids [57] . The increased methylation of cg14795968 in patients with narcolepsy, located in a CpG island region in the first intron of ACADL, might contribute to dysfunctional fatty acid β-oxidation pathway and the gene is therefore considered an interesting candidate for future studies.
An important aim of this study was to identify DMPs implicated in the etiology of narcolepsy. It is impossible to know whether different levels of methylation have a causal role in a disease from EWAS data alone, because DNA methylation can be altered as a consequence of the disease. Hence, we performed an integrative analysis of GWAS and EWAS data to identify DMPs whose methylation levels were changed according to the genotypes of narcolepsy-associated SNPs, since these are likely to have a causal effect on the disease. Nineteen meQTLs relevant to one methylation site in the CCR3 region were identified, and the SNPs of these meQTLs were in high LD. As the sample size of the present EWAS was not so large, careful discussion should also be made for the result of the integrative analysis; however, CCR3 itself might play a certain role in the narcoleptic etiology. In our previous GWAS, we reported that SNP rs3181077, located between CCR1 and CCR3, was associated with narcolepsy, and that CCR1 and CCR3 Each node represents a significant gene set and the numbers of nodes correspond to the Indexes in Table 2 . The node size is proportional to the number of genes in a gene set. Edges represent the number of genes shared by any two gene sets, and edge width is proportional to the number of shared genes. The positions of each node were determined based on multidimensional scaling. mRNA levels were significantly lower in patients with narcolepsy [13] . We found that CCR1 mRNA levels changed according to the genotype of SNP rs3181077, whereas CCR3 levels were not related to this genotype. Although SNP rs3181077 and the SNPs of the identified meQTLs in the present study are in moderate LD (r 2 : 0.58 − 0.59), it is possible that CCR3 expression is mainly affected by the SNPs and methylation level linked to these meQTLs. CCR3 encodes a G protein-coupled receptor for C-C type chemokines, which play a central role in the inflammatory recruitment of leukocytes and other cells into the central nervous system [58] . Accumulating evidence suggests that there is an autoimmune basis of narcolepsy [59] . In addition, a recent study reported that Ccr3 KO mice had fewer orexin neurons and exhibited more fragmented sleep patterns in the light phase [60] . Therefore, CCR3 might be an important candidate for further investigation in this regard. There are several limitations to consider in this study. First of all, the number of methylation sites examined and the sample size were relatively small. Illumina's Methylation 27K BeadChip can determine the DNA methylation profile for 27 578 CpGs, spanning 14 495 genes. DNA methylation has been reported to be regionally correlated in a similar fashion to that of LD correlations for SNPs; however, the length of regions with correlated methylation tends to be much shorter than for SNP LD [61] . As such, the methylation array used in this study cannot provide coverage across the whole genome. Additional studies using newer array platforms or sequencing-based methods are required to address this issue. Secondly, all DNA samples analyzed in this study were extracted from whole blood. Since immune abnormality is thought to play an important role in the etiology of narcolepsy, the methylation profile of leukocytes provides important clues in regard to the molecular mechanisms driving these diseases. However, in order to investigate disease-associated DMPs responsible for sleep wake regulation specifically in the brain, studies using DNA from brain neuronal cells will be necessary. Finally, the methylation sites which were detected as possible disease-associated DMPs were not examined using an independent cohort or with other methods such as pyrosequencing. Future studies are necessary to confirm the findings of this study and elucidate the functional relevance of the identified loci in the pathophysiology of narcolepsy.
In conclusion, our study of the DNA methylation profile of narcolepsy patient blood samples returned the three major findings: (1) Genes annotated to the top-ranked narcolepsy-associated DMPs were associated with pathways of hormone secretion and monocarboxylic acid metabolism. (2) Top-ranked DMPs were significantly more abundant in non-CpG island regions and more than 95 per cent of such sites were hypomethylated in patients with narcolepsy. (3) The integrative analysis identified the CCR3 region where both a single methylation site and multiple SNPs were found to be associated with the disease as a candidate region responsible for narcolepsy. Future replication studies, using methylation technologies with greater genome coverage, as well as larger numbers of samples are now warranted to confirm these findings.
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